Siemens Healthineers finalizes $1.1B robotics acquisition

Siemens Medical Solutions, a wholly-owned subsidiary of Siemens Healthineers AG, has completed its acquisition of 100% of Waltham, Massachusetts-based Corindus Vascular Robotics. The deal, which was for $1.1 billion, was first announced back in August.

Corindus specializes in robotic-assisted intervention, allowing physicians to perform minimally invasive procedures in a way that reduces strain and fatigue and provides “point and shoot” navigation. Mark J. Toland, president and CEO of Corindus before this acquisition, will still manage the business moving forward.

“The combination of Siemens Healthineers’ strong medical technology portfolio with its digital platforms and solutions, together with Corindus’ precision robotics platform, has the potential to transform healthcare delivery so that, together, we can provide better care at lower cost,” Toland said in a prepared statement.

Corindus is now part of the advanced therapies reporting segment at Siemens Healthineers.

“With the completion of the acquisition, we are opening up a new field for our Advanced Therapies business, tapping into adjacent growth markets with great potential for the future,” Bernd Montag, CEO of Siemens Healthineers, said in the same statement.  

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.